The Beryllium BioBank consists of a Data Coordinating Center and a Core Specimen Laboratory, housed at National Jewish Health in Denver, Colorado.
The Department of Energy, assisted by a group of clinicians and scientists from National Jewish Health, the Hospital of the University of Pennsylvania, East Tennessee Pulmonary Associates, University of California-San Francisco, and University of California- Los Angeles, collected clinical data and specimens for the Beryllium BioBank. The purpose of the repository is to facilitate research by collecting de-identified biological specimens and clinical information from a large number of workers exposed to beryllium. The BioBank does not directly conduct research.
The BioBank is a resource for future researchers to:
- Identify exposure and genetic risk factors that cause beryllium sensitization and disease
- Improve the detection of beryllium sensitization and CBD
- Define new therapeutics to be tested in the treatment of CBD
- Understand the immune and inflammatory mechanisms that cause beryllium sensitization and CBD
- Develop new biological markers of exposure, biological effect, and disease
- Define clinical and physiologic aspects of beryllium sensitization and CBD
This effort is funded by the U.S. Department of Energy.
Questions about the Beryllium BioBank?
Lisa A. Maier, MD, MSPH, FCCP
National Jewish Health
1400 Jackson St., G204
Denver, CO 80206
Briana Barkes, MPH